LXRX
NASDAQLexicon Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks53+300%
2026-03-012026-08-23
Mix1990d
- Insider7(37%)
- Other5(26%)
- SEC Filings5(26%)
- Earnings2(11%)
Latest news
25 items- SECSEC Form EFFECT filed by Lexicon Pharmaceuticals Inc.EFFECT - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- FDAFDA Approval for INPEFA issued to LEXICON PHARMS INCSubmission status for LEXICON PHARMS INC's drug INPEFA (SUPPL-3) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 08/06/2026. Application Category: NDA, Application Number: 216203, Application Classification: Labeling
- SECSEC Form S-3 filed by Lexicon Pharmaceuticals Inc.S-3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECSEC Form S-8 filed by Lexicon Pharmaceuticals Inc.S-8 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECSEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexicon Pharmaceuticals Inc.SCHEDULE 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- PRLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical UpdatesEnrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments. "Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our busin
- PRLexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast
- PRLexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that randomization of patients has been completed in the pivotal Phase 3 "SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)" clinical trial evaluating sotagliflozin in patients with non-obstructive (nHCM) and obstructive (oHCM) hypertrophic cardiomyopathy. The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries. The primary efficacy endpoint wil
- INSIDERDirector Swain Judith L converted options into 89,312 shares, increasing direct ownership by 105% to 174,486 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Sullivan Diane E. converted options into 89,312 shares, increasing direct ownership by 243% to 126,122 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Sobecki Christopher J converted options into 89,312 shares, increasing direct ownership by 44% to 293,177 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Cheung Ivan converted options into 89,312 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Amouyal Philippe converted options into 89,312 shares, increasing direct ownership by 31% to 374,486 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Barker Sam L converted options into 89,312 shares, increasing direct ownership by 72% to 213,771 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Debbane Raymond converted options into 89,312 shares, increasing direct ownership by 5% to 1,995,498 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- PRLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsTHE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Diabetes Association (ADA) 2026 Scientific Sessions, being held June 5-8 in New Orleans, Louisiana. "We look forward to engaging with the diabetes community at ADA 2026, as well as sharing additional data from clinical studies of our novel, orally administered investigational therapies for T1D and DPNP," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "In particul
- PRLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceTHE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic car
- PRLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceTHE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical deve
- INSIDERDirector Artal Participations S.A R.L. converted options into 20,421,735 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- SECSEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- PRLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesSONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. "We have been intently focused on progressing our la
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
LXRX FAQ
6 questionsWhat does Lexicon Pharmaceuticals Inc. do?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was...Where does LXRX stock trade?
Lexicon Pharmaceuticals Inc. (LXRX) is listed on NASDAQ.What sector and industry is LXRX in?
Lexicon Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LXRX?
Lexicon Pharmaceuticals Inc. has had 5 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $100.00 price target on 2025-03-05.What companies are similar to LXRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LXRX side-by-side with any of them on Quantisnow.How can I track LXRX on Quantisnow?
Quantisnow aggregates Lexicon Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LXRX to receive live email and push alerts on every new disclosure.